CHE
Chemed Corporation
CHE's fundamentals are mixed: it turned 11% of its revenue into free cash flow. At 26x earnings, it's trading in line with its usual 29x. Analysts expect earnings growth.
CHE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Healthy |
CHE's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CHE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $550 | — |
| Cheap | 24x | $500 | -9.2% |
| Current | 26x | $550 | — |
| Fair | 29x | $602 | +9.5% |
| Expensive | 34x | $710 | +29% |
Historical ranges are pointers, not guarantees.
CHE's PE is in its cheap range at 26x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
CHE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CHE, with profitability holding steady.
CHE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $27.06 | +30% |
| Q3 2026 | $20.87 | +10% |
| Q2 2026 | $19.88 | +2.3% |
| Q1 2026 | $18.32 | -11% |
| Q4 2025 | $18.34 | -7.8% |
| Q3 2025 | $18.89 | -4.6% |
| Q2 2025 | $19.43 | -1.5% |
| Q1 2025 | $20.51 | +10% |
| Q4 2024 | $19.89 | +11% |
CHE earned $20.87 per share over the past year, up 10% from the year before.
CHE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $690.9M | +11% |
| Q2 2026 | $673.3M | +8.8% |
| Q1 2026 | $657.5M | +1.6% |
| Q4 2025 | $639.3M | -0.1% |
| Q3 2025 | $624.9M | +3.1% |
| Q2 2025 | $618.8M | +3.8% |
| Q1 2025 | $646.9M | +9.8% |
| Q4 2024 | $640M | +9.2% |
CHE's revenue is growing: $691M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +2 points |
| Q2 2026 | 13% | +2.3 points |
| Q1 2026 | 13% | -1.8 points |
| Q4 2025 | 16% | -2 points |
| Q3 2025 | 12% | -3.2 points |
| Q2 2025 | 11% | -3.8 points |
| Q1 2025 | 15% | +2.4 points |
| Q4 2024 | 18% | -1.2 points |
CHE's operating margin was 14% last quarter, up 2 points from the same quarter a year ago.
CHE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $37.9M | -43% |
| Q2 2026 | $69.3M | -44% |
| Q1 2026 | $71.1M | +265% |
| Q4 2025 | $117.2M | -23% |
| Q3 2025 | $65.9M | -14% |
| Q2 2025 | $122.8M | +85% |
| Q1 2025 | $19.5M | -73% |
| Q4 2024 | $152.2M | +57% |
CHE's free cash flow has been positive every quarter for seven years: $295M over the past year, down 18% from the year before.
CHE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -64K shares |
| 1 year | -8.8% | -1.3M shares |
| 3 years | -14% | -2.1M shares |
| 5 years | -17% | -2.7M shares |
| Available history | -21% | -3.4M shares |
CHE has 13M diluted shares, down 8.8% from a year ago, with $525M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $62.5M |
| Q2 2026 | $97.5M |
| Q1 2026 | $190M |
| Q4 2025 | $174.6M |
| Q3 2025 | $180.8M |
| Q2 2025 | $42.9M |
| Q1 2025 | $33.2M |
| Q4 2024 | $209.3M |
CHE spent $525M buying back its own shares over the past year, up 13% from the year before.
CHE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
CHE's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CHE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.7 | Neutral |
| Stochastic | 65.1 | Neutral |
CHE's weekly RSI is 66 (neutral) and its Stochastic is 65 (neutral).
CHE PE vs Healthcare Sector
| Metric | CHE | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 2% above |
| PE % | 32 | 29 | 3 pts above |
CHE is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
CHE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $519.7 | 5.9% above |
| 20 week MA | $518.9 | 6% above |
| 50 week MA | $462.7 | 19% above |
| 100 week MA | $488.0 | 13% above |
| 200 week MA | $523.0 | 5.2% above |
CHE has climbed back above all five of its weekly moving averages, and it's now 5.2% above its 200-week average.
CHE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $438.7 | $536.7 | +22% |
| 2021 | $536.7 | $525.3 | -2.1% |
| 2022 | $525.3 | $516.2 | -1.7% |
| 2023 | $516.2 | $584.8 | +13% |
| 2024 | $584.8 | $522.8 | -11% |
| 2025 | $522.8 | $432.2 | -17% |
| 2026 YTD | $432.2 | $550.2 | +27% |
CHE has finished lower in four of the last six years. It's up 27% so far in 2026.